Nurix Therapeutics

Nurix Therapeutics NRIX Stock

$14.10   -0.983142%
Add to favorites
Market Cap
$1.54B
LOW - HIGH [24H]
$13.65 - $14.44
VOLUME [24H]
$2.79M
P/E Ratio
5.80
Earnings per share
$2.43
ISIN
US67080M1036
Price   Prediction

Nurix Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Nurix Therapeutics (NRIX) stock price today is 14.1 USD on Tech Market Middle (-0.98% on the day). Updated .

Nurix Therapeutics NRIX Financial and Trading Overview

Nurix Therapeutics stock price 14.1 USD
Previous Close 14.73 USD
Open 14.8 USD
Bid 18.13 USD x 200
Ask 31.75 USD x 200
Day's Range 14.11 - 14.86 USD
52 Week Range 12.61 - 28.23 USD
Volume 2.22M USD
Avg. Volume 2.43M USD
Market Cap 1.56B USD
Beta (5Y Monthly) 1.779
PE Ratio (TTM) 5.860082
EPS (TTM) 2.43 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 33.5 USD

NRIX Valuation Measures

Enterprise Value 572.79M USD
Trailing P/E 5.860082
Forward P/E -11.163374
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 2.2163236
Price/Book (mrq) 1.6059546
Enterprise Value/Revenue 0.816
Enterprise Value/EBITDA 1.924

Trading Information

Nurix Therapeutics Stock Price History

Beta (5Y Monthly) 1.779
52-Week Change -0.62%
S&P500 52-Week Change 10.51%
52 Week High 28.23 USD
52 Week Low 12.61 USD
50-Day Moving Average 22.8 USD
200-Day Moving Average 20.1 USD

NRIX Share Statistics

Avg. Volume (3 month) 2.43M USD
Avg. Daily Volume (10-Days) 5.03M USD
Shares Outstanding 109.25M
Float 79.58M
Short Ratio 7.69
% Held by Insiders 1.02%
% Held by Institutions 110.00%
Shares Short 18.94M
Short % of Float 17.51%
Short % of Shares Outstanding 17.33%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends November 30, 2025
Most Recent Quarter (mrq) August 31, 2026
Next Fiscal Year End November 30, 2026

Profitability

Profit Margin 42.00%
Operating Margin (ttm) 41.26%
Gross Margin 52.40%
EBITDA Margin 42.42%

Management Effectiveness

Return on Assets (ttm) 21.07%
Return on Equity (ttm) 43.99%

Income Statement

Revenue (ttm) 701.94M USD
Revenue Per Share (ttm) 6.56 USD
Quarterly Revenue Growth (yoy) 8426.30%
Gross Profit (ttm) 367.86M USD
EBITDA 297.77M USD
Net Income Avi to Common (ttm) 294.88M USD
Diluted EPS (ttm) 2.43
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 1.05B USD
Total Cash Per Share (mrq) 9.6 USD
Total Debt (mrq) 65.33M USD
Total Debt/Equity (mrq) 6.75 USD
Current Ratio (mrq) 8.442
Book Value Per Share (mrq) 8.867

Cash Flow Statement

Operating Cash Flow (ttm) 379.31M USD
Levered Free Cash Flow (ttm) 233.34M USD

Profile of Nurix Therapeutics

Country United States
State CA
City Brisbane
Address 1600 Sierra Point Parkway
ZIP 94005
Phone 415 660 5320
Website https://www.nurixtx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 317

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Q&A For Nurix Therapeutics Stock

What is a current NRIX stock price?

Nurix Therapeutics NRIX stock price today per share is 14.1 USD.

How to purchase Nurix Therapeutics stock?

You can buy NRIX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Nurix Therapeutics?

The stock symbol or ticker of Nurix Therapeutics is NRIX.

Which industry does the Nurix Therapeutics company belong to?

The Nurix Therapeutics industry is Biotechnology.

How many shares does Nurix Therapeutics have in circulation?

The max supply of Nurix Therapeutics shares is 109.25M.

What is Nurix Therapeutics Price to Earnings Ratio (PE Ratio)?

Nurix Therapeutics PE Ratio is 5.80246930 now.

What was Nurix Therapeutics earnings per share over the trailing 12 months (TTM)?

Nurix Therapeutics EPS is 2.43 USD over the trailing 12 months.

Which sector does the Nurix Therapeutics company belong to?

The Nurix Therapeutics sector is Healthcare.

Nurix Therapeutics NRIX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24429.89 USD —
+0.42
7.16B USD — 24225.3 USD — 24538.78 USD — — 7.16B USD —
us US Tech Global Market Composite NQGM US 1839.01 USD —
+0.18
— — 1830.2 USD — 1855.92 USD — — — —
us US Tech Biotechnology NBI US 6971.7 USD —
-0.66
— — 6959.96 USD — 7076.43 USD — — — —
us US Tech Health Care IXHC US 1324.44 USD —
-0.63
— — 1322.85 USD — 1342.46 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.16T
Total marketcap
$70.5B
Total volume
BTC 57.96%   •   ETH 9.95%
Dominance
Select currency